Ocugen, INC DEF 14A proxy statements

Ocugen is holding a special meeting on September 21, 2026, to seek shareholder approval to amend its charter to increase the number of authorized common stock shares by 250 million.

Ocugen provides an update on its gene therapy programs, clinical trial progress, and upcoming annual meeting of stockholders.

Ocugen, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Ocugen is advancing its ophthalmology clinical programs, with a focus on modifier gene therapy and aiming for three Biologics License Applications (BLA) filings in the next three years.

Ocugen's upcoming annual meeting will proceed with a revised agenda following Ernst & Young's decision to decline re-election as the company's independent auditor.

Ocugen's proxy statement outlines proposals for the upcoming annual meeting, including limiting officer liability, increasing authorized shares, and adjusting voting requirements.